IL-17A and IL-23 cytokines and their relation with estrogen in post menopausal osteoporosis

Shah Waliullah, Vineet Sharma, RN Srivastava, Yashodhara Pradeep, AA Mahdi and Santosh Kumar

DOI: https://doi.org/10.22271/ortho.2018.v4.i1m.12

Abstract

Introduction: Estrogen deficiency is now considered as post inflammatory state as it has been associated with elevation of various cytokines like IL-1 IL-6 and TNF-α, responsible for osteoclastogenesis. Role of IL-17 has been established in various inflammatory and auto-immune disorders associated with bone loss, we evaluated the levels of IL-17 with respect to estrogen in post menopausal women with and without osteoporosis.

Material & Methods: Total 75 post menopausal females with mean age (58.17±5.94), between age group 45-75years were recruited. Females with history of natural menopause at least one year after the onset of menopause were enrolled. All patients underwent BMD measurement through Dual energy X-ray absorptiometry (DEXA) scan and divided into two groups, Group A patients with osteoporosis and Group B without osteoporosis. Serum level of IL-17, IL-23 levels and Estrogen level were measured by standard quantitative sandwich ELISA kits.

Results: Group A patients level of IL-17(48.49±8.34 pg/ml) and IL-23(91.28±9.89 pg/ml) was significantly higher than in group B patients with level of IL-17(19.55±7.11 pg/ml), IL-23 (44.56±11.36 pg/ml) while that of estrogen was significantly low in group A (31.80±12.57 pg/ml) in comparison to group B (40.39±20.88 pg/ml).

Conclusion: We observed lower level of estrogen is associated with higher level of inflammatory cytokines IL-17 and IL-23, thus further strengthening the concept that post menopausal osteoporosis is inflammatory disorder as estrogen deficiency results in elevation of inflammatory cytokines.

Keywords: IL-17, IL-23, Estrogen, Post Menopausal osteoporosis

Introduction

Post menopausal osteoporosis defined as a silent skeletal disorder characterised by compromised bone strength predisposing to increased risk of fracture [1]. Post-menopausal osteoporosis (type I) is commonest form of the osteoporosis and is believed to start with the deficiency of estrogen following menopause [2]. Estrogen affect both osteoclast as well as osteoblast, due to deficiency of estrogen, there is incoordination in activity between osteoclast and osteoblast, increased osteoclastic activity without adequate bone formation by osteoblast resulting into thinning of trabeculae and bone resorption. Bone becomes thin, brittle and vulnerable to fracture.

Estrogen deficiency is now considered as post inflammatory state as it has been associated with elevation of various cytokines like IL-1 IL-6 and TNF-α [4-5,6]. These cytokines primarily results in osteoclastogenesis associated with estrogen deficiency.

IL-17, a unique cytokine, produced by T helper subset named Th17, has been linked with osteoclastogenesis in bone loss in various disorders like rheumatoid arthritis, multiple sclerosis, Crohn disease, psoriatic arthritis [7, 8, 9, 10]. Role of IL-17 in post menopausal osteoporosis has been studied in animal model and it has been found to be responsible for mediating osteoclastogenesis, we evaluated the levels of IL-17 with respect to estrogen in post menopausal women with and without osteoporosis.

Material & Methods

This study was conducted in the department of orthopaedic surgery. Informed consent was obtained from all patients. Total 75 post menopausal females with mean age (58.17±5.94), between age group 45-75years were recruited. Females with history of natural menopause at least one year after the onset of menopause were enrolled. All patients underwent BMD measurement through Dual energy X-ray absorptiometry (DEXA) scan and divided into two groups, Group A patients with osteoporosis and Group B without osteoporosis. Serum level of IL-17, IL-23 levels and Estrogen level were measured by standard quantitative sandwich ELISA kits.

Results: Group A patients level of IL-17(48.49±8.34 pg/ml) and IL-23(91.28±9.89 pg/ml) was significantly higher than in group B patients with level of IL-17(19.55±7.11 pg/ml), IL-23 (44.56±11.36 pg/ml) while that of estrogen was significantly low in group A (31.80±12.57 pg/ml) in comparison to group B (40.39±20.88 pg/ml).

Conclusion: We observed lower level of estrogen is associated with higher level of inflammatory cytokines IL-17 and IL-23, thus further strengthening the concept that post menopausal osteoporosis is inflammatory disorder as estrogen deficiency results in elevation of inflammatory cytokines.

Keywords: IL-17, IL-23, Estrogen, Post Menopausal osteoporosis
taken from each subject participating in this study and ethical clearance for the study was obtained from the Ethics Committee of the university. Total 75 post menopausal females with mean age (58.17±5.94), between age group 45-75 years were recruited. Females with history of natural menopause at least one year after the onset of menopause were enrolled. All patients filled a questionnaire pertaining their demographic variables, menstrual history, physical activity, exercise history and dietary intake. Females with history of surgical menopause or suffering from any chronic inflammatory disorder affecting bone turn over metabolism like chronic liver disorders, renal disorder, thyroidism, hyperparathyroidism, rheumatoit arthritis, auto-immune disorders and malignancy were excluded from our study.

Patients with a history of medications like steroid intake or any other drug affecting bone turnover metabolism were also excluded. All patients underwent BMD measurement through DEXA scan. BMD was measured at lumbar spine. DEXA scan was interpreted in terms of T score as per World Health Organisation (WHO) guidelines [11]. All patients were divided into two groups, Group A patients with osteoporosis with T score lesser than -2.5 and Group B without osteoporosis with T score greater than -1.

Venous blood sample was collected from all subjects. After centrifugation at 4000 rotation per minute, serum was separated and stored at -80 degree celsius. Serum level of IL-17, IL-23 levels and Estrogen level were measured by standard quantitative sandwich ELISA kits according to the manufacturer’s instructions as per standard protocols.

**Results**

Group A includes 39 patients with osteoporosis (mean T score-3.61±1.06) and Group B includes 36 patients without osteoporosis (mean T score-0.45±1.15). In group A patients level of IL-17(48.49±8.34 pg/ml) and IL-23(91.28±9.89 pg/ml) was significantly higher than in group B with level of IL-17 19.55±7.11 pg/ml), IL-23 (44.56±11.36 pg/ml) while that of estrogen was significantly low in group A (31.80±12.57 pg/ml) in comparison to group B (40.39±20.88 pg/ml). Levels of IL-17, IL-23 and estrogens were found to be statistically significant among both groups (p value<.05).

<table>
<thead>
<tr>
<th>(Mean±SD)</th>
<th>Group A (n=39)</th>
<th>Group B (n=36)</th>
<th>p-value1</th>
</tr>
</thead>
<tbody>
<tr>
<td>T Score AP Spine L1-L4</td>
<td>-3.61±1.06</td>
<td>-0.45±1.15</td>
<td>0.0001*</td>
</tr>
<tr>
<td>IL-17 (pg/ml)</td>
<td>48.49±8.34</td>
<td>19.55±7.11</td>
<td>0.001*</td>
</tr>
<tr>
<td>IL-23 (pg/ml)</td>
<td>91.28±9.89</td>
<td>44.56±11.36</td>
<td>0.001*</td>
</tr>
<tr>
<td>Estrogen (pg/ml)</td>
<td>31.80±12.57</td>
<td>40.39±20.88</td>
<td>0.003*</td>
</tr>
</tbody>
</table>

*Unpaired t-test, *Significant

Comparison of IL-17, IL-23 and Estrogen

**Discussion**

IL-17 is produced by T helper subset named Th17, has a key role in inflammatory arthritis and other diseases affecting the bone metabolism [12]. Its role in rheumatoid arthritis has been extensively studied in human as well as in animal studies. It was found to be elevated in synovial fluids of patients with rheumatoid arthritis [13, 14]. Role of IL-17 has also been extensively established with osteoclastogenesis in various auto-immune disorders associated with bone loss [15]. IL-17 has been found as crucidal regulator of osteoclastogenesis associated with estrogen deficiency in animal studies. Tyagi et al. [16] studied the effect of estrogen on Th17 differentiation and IL-17 mediated regulation of osteoclast and osteoblast in murine models. He observed that estrogen deficiency in ovaricectomized mice induces Th17 cells differentiation, increased IL-17 cytokines levels and these effects are further reverse by estrogen treatment. Increased IL-17 levels were associated with decrease mineralization of bone. De Selma [17] observed that blocking IL-17 signaling prevents estrogen deficiency mediated osteoporosis by inhibiting osteoclastogenesis in animal model. Molnar et al. [18] in his study on human subjects observed strong association of estrogen deficiency with elevated IL-17 level in post menopausal females. He further showed that post menopausal osteoporotic subjects have been associated with elevated level of IL-17A and soluble receptor activator of NF-kB (sRANK ligand levels), responsible for osteoclastogenesis. In our study, we also observed elevated level of IL-17 in post menopausal females with estrogen deficiency. Thrawa et al [19] also observed elevated level of IL-17 in post menopausal osteoporosis females.

**Conclusion**

In our study on post menopausal females, we observed lower level of estrogen is associated with higher level of inflammatory cytokines IL-17 and IL-23, thus further strengthening the concept that post menopausal osteoporosis is inflammatory disorder as estrogen deficiency results in elevation of inflammatory cytokines.

**References**


